Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Coronary heart disease (CHD) patients with dyslipidemia face elevated cardiovascular event risk.
• Low high-density lipoprotein cholesterol (HDL-C) and high triglyceride levels are key risk factors.
• The clinical benefit of lipid-modifying therapies like bezafibrate requires further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of bezafibrate in reducing cardiovascular events in CHD patients.
• To assess the impact of bezafibrate on HDL-C and triglyceride levels.
• To explore potential benefits in specific patient subgroups.

Main Methods:

• A double-blind, placebo-controlled trial involving 3090 patients with previous myocardial infarction or stable angina.
• Patients received either bezafibrate (400 mg/day) or placebo for a mean of 6.2 years.
• Primary endpoint: fatal/nonfatal myocardial infarction or sudden death. Secondary analysis: subgroup with high baseline triglycerides (> or =200 mg/dL).

Main Results:

• Bezafibrate significantly increased HDL-C by 18% and reduced triglycerides by 21%.
• No significant difference in the primary endpoint between bezafibrate and placebo groups (13.6% vs 15.0%, P=0.26).
• A significant 39.5% reduction in primary endpoint events was observed in the subgroup with high baseline triglycerides (P=0.02).

Conclusions:

• Bezafibrate is safe and effective in improving lipid profiles (increasing HDL-C, decreasing triglycerides).
• An overall trend towards reduced cardiovascular events was noted, though not statistically significant.
• The observed benefit in high triglyceride subgroups warrants further confirmation and suggests a potential therapeutic niche.